Cometriq is a prescription medication used to treat a certain type of thyroid cancer that has spread to other parts of the body. Cometriq belongs to a group of drugs called tyrosine kinase inhibitors. It works by slowing or stopping the growth of cancer cells. Cometriq (cabozantinib) was approved for progressive, metastatic medullary thyroid cancer (MTC)1,2 by: FDA (USA) on November 29, 2012 and EMA (EU) on March 26, 2014

Where can I buy Cometriq?

Indian Pharma Network (IPN) New Delhi, INDIA.

IPN is a facilitator under Patient Assistance Programs. Expertise in Specialty Pharmaceutical distribution having its PAN India presence in Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, lucknow and Pune and other cities in India. with over 20 years of domain experience.

The order for Cometriq (cabozantinib) will be confirmed only after the receipt of valid prescription of doctor and import permit if applicable.

For Cometriq or cabozantinib price in India. Please call at M: +91 9811747774 or Email us at to know more details about the medicine and its cost price in India.
Cometriq (cabozantinib)

Get In Touch

Facilitator under Patient Assistance Programs In India

IPN helps patients, doctors and hospitals as a facilitator to import prescription medicine brand Cometriq (cabozantinib) on prescription and Import License in Patient's Name only.

For overseas patients, Cometriq (cabozantinib) Tablets can be made available in Send your enquiry to find Cometriq (cabozantinib) Tablets in China, Cambodia, Indonesia, Malaysia, the Philippines, Singapore, Thailand, Vietnam, Hong Kong. UAE Iraq, Iran, Saudi Arabia, Jordan, Mexico, Argentina, Brazil, Chile, Colombia, Peru, Venezuela. Europe – Romania, Switzerland, Georgia, Turkey, Italy, UK, Ukraine, Azerbaijan, Latvia, Poland, Slovakia. Russia CIS – Armenia, Kazakhstan, Moldova, Tajikistan, Turkmenistan, Uzbekistan, Mongolia, Algeria, Mauritius, Uganda, Zimbabwe. Australia and New Zealand.

Dosage Forms and Strengths

20 mg and 80 mg capsules.


Immuno Oncology News

NICE has recommended that two thyroid cancer drugs, Ipsen’s Cometriq (cabozantinib) and Bayer’s Nexavar (sorafenib), should come off the Cancer Drugs Fund and into routine NHS use..
Dated: 19th February 2018